Spots Global Cancer Trial Database for parsaclisib
Every month we try and update this database with for parsaclisib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor | NCT03235544 | Lymphoma | Parsaclisib | 18 Years - | Incyte Corporation | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | NCT03144674 | Lymphoma | Parsaclisib | 18 Years - | Incyte Corporation | |
| A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | NCT02718300 | MPN (Myeloproli... | Parsaclisib Parsaclisib Ruxolitinib Parsaclisib Parsaclisib | 18 Years - | Incyte Corporation | |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. | NCT04831944 | Advanced Malign... | parsaclisib | 18 Years - 80 Years | Incyte Corporation | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | NCT04774068 | Recurrent Anapl... Recurrent Matur... Recurrent Prima... Recurrent Trans... Refractory Anap... Refractory Matu... Refractory Prim... Refractory Tran... T-Cell Non-Hodg... | Parsaclisib Romidepsin | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. | NCT04831944 | Advanced Malign... | parsaclisib | 18 Years - 80 Years | Incyte Corporation | |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT04849715 | Mantle Cell Lym... | parsaclisib rituximab bendamustine Placebo | 18 Years - | Incyte Corporation | |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | NCT03314922 | Lymphoma | Parsaclisib | 20 Years - | Incyte Corporation | |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | NCT04509700 | B-Cell Malignan... | Parsaclisib parsaclisib + i... parsaclisib + r... parsaclisib + i... | 18 Years - | Incyte Corporation | |
| Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) | NCT04434937 | Lymphoma | parsaclisib | 18 Years - | Incyte Corporation | |
| A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor | NCT03235544 | Lymphoma | Parsaclisib | 18 Years - | Incyte Corporation | |
| Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | NCT05867030 | Follicular Lymp... | lenalidomide rituximab parsaclisib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | NCT04551066 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) | NCT02018861 | B-Cell Malignan... | Parsaclisib Itacitinib Rituximab Ifosfamide Carboplatin Etoposide | 18 Years - | Incyte Corporation | |
| A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) | NCT02998476 | Lymphoma | Parsaclisib | 18 Years - | Incyte Corporation | |
| A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma | NCT03126019 | Lymphoma | Parsaclisib | 18 Years - | Incyte Corporation | |
| INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | NCT03424122 | B-cell Lymphoma | Parsaclisib Rituximab Bendamustine Ibrutinib | 18 Years - | Incyte Corporation | |
| Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer | NCT04142554 | Breast Cancer Breast Neoplasm... Triple Negative... HER2-positive B... | Parsaclisib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | NCT04551053 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | NCT04661007 | Non Hodgkins Ly... Diffuse Large B... | tafasitamab lenalidomide parsaclisib R-CHOP | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
